Sulfuric Acid

SCHEMBL11906224

CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O.CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 ADRB3 CALCRL CHRM1 CHRM2 CHRM3 F2R MAOA MAOB MAP2K1 MAP2K2 NTRK1 NTRK2 NTRK3 OPRD1 OPRK1 OPRM1 P2RY12 PKLR SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SLC18A2 SLC6A2 SLC6A3 TLR7 TLR9 TUBA1A TUBA1B TUBA1C TUBA3C TUBA3E TUBA4A TUBB TUBB1 TUBB2A TUBB2B TUBB3 TUBB4A TUBB4B TUBB6 TUBB8 dacA dacB dacC folA ftsI mrcA mrcB mrdA pol rplA rplB rplC rplD rplE rplF rplI rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmB1 rpmB2 rpmC rpmD rpmE rpmE2 rpmF rpmG rpmG1 rpmG2 rpmH rpmI rpmJ rpmJ2 rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsR1 rpsR2 rpsS rpsT rpsU rpsZ ykgM ykgO

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	KDM1A	O60341	4/20	0.95

▸	RCOR1	Q9UKL0	3/20	0.85

▸	LDHB	P07195	4/20	0.42

▸	TERF2IP	Q9NYB0	2/20	0.38

▸	ESR1	P03372	1/20	0.35

▸	ESR2	Q92731	1/20	0.35

▸	HDAC3	O15379	1/20	0.35

▸	HDAC4	P56524	1/20	0.35

▸	HDAC1	Q13547	1/20	0.35

▸	HDAC7	Q8WUI4	1/20	0.35

▸	HDAC2	Q92769	1/20	0.35

▸	HDAC10	Q969S8	1/20	0.35

▸	HDAC11	Q96DB2	1/20	0.35

▸	HDAC8	Q9BY41	1/20	0.35

▸	HDAC6	Q9UBN7	1/20	0.35

▸	HDAC9	Q9UKV0	1/20	0.35

▸	HDAC5	Q9UQL6	1/20	0.35

▸	KEAP1	Q14145	1/20	0.35

▸	NPY1R	P25929	1/20	0.35

▸	NPY2R	P49146	1/20	0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Sulfuric Acid SCHEMBL14637227	1.00	KDM1A (0.95)	KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL31066574	0.97	KDM1A (1.00)	KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL18902532	0.97	KDM1A (1.00)	KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL49226	0.97	KDM1A (1.00)	KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL21476977	0.97	KDM1A (1.00)	KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL25641510	0.97	KDM1A (0.99)	KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL21474097	0.97	KDM1A (0.99)	KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL29394303	0.97	KDM1A (0.99)	KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL14845813	0.97	KDM1A (0.99)	KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL21474060	0.96	KDM1A (0.96)	KDM1ARCOR1LDHBTERF2IPESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
CN-118453541-A	Preparation of compound antibacterial drug nanometer slow-release microsphere	河南农业大学	2024-08-09	—	—	CN	claimed
CN-118359686-A	Preparation method of polymyxin E sodium mesylate	河北圣雪大成制药有限责任公司	2024-07-19	—	—	CN	claimed
CN-118453541-A	Preparation of compound antibacterial drug nanometer slow-release microsphere	河南农业大学	2024-08-09	—	—	CN	disclosed
CN-118453541-A	Preparation of compound antibacterial drug nanometer slow-release microsphere	河南农业大学	2024-08-09	—	—	CN	disclosed
CN-118359686-A	Preparation method of polymyxin E sodium mesylate	河北圣雪大成制药有限责任公司	2024-07-19	—	—	CN	disclosed
CN-118359686-A	Preparation method of polymyxin E sodium mesylate	河北圣雪大成制药有限责任公司	2024-07-19	—	—	CN	disclosed
US-10711040-B2	Low substituted polymyxins and compositions thereof	XELLIA PHARMACEUTICALS APS (DK)	2020-07-14	—	—	US	disclosed
US-10640536-B2	Polymyxins, compositions, methods of making and methods of use	XELLIA PHARMACEUTICALS APS (DK)	2020-05-05	—	—	US	disclosed
WO-2019168421-A1	A METHOD FOR ISOLATION OF PURE POLYMYXIN E SULFATE COMPONENT	UNIWERSYTET WARSZAWSKI (PL)	2019-09-06	—	—	WO	disclosed
EP-3166960-B1	LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF	XELLIA PHARMACEUTICALS APS (DK)	2019-08-07	—	—	EP	disclosed
EP-2943503-B1	POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE	XELLIA PHARMACEUTICALS APS (DK)	2017-08-23	—	—	EP	disclosed
US-20170218024-A1	LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF	XELLIA PHARMACEUTICALS APS (DK)	2017-08-03	—	—	US	disclosed
US-20160002296-A1	POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE	XELLIA PHARMACEUTICALS APS (DK)	2016-01-07	—	—	US	disclosed
US-9005990-B2	Method for purification of colistin and purified colistin components	XELLIA PHARMACEUTICALS APS (DK)	2015-04-14	—	—	US	disclosed
EP-2470555-B1	METHOD FOR PURIFICATION OF COLISTIN AND PURIFIED COLISTIN COMPONENTS	XELLIA PHARMACEUTICALS APS (DK)	2014-12-24	—	—	EP	disclosed
US-20120208981-A1	Method for purification of colistin and purified colistin components	XELLIA PHARMACEUTICALS APS (DK)	2012-08-16	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20160002296-A1	POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE	C5, SGMS1, SGMS2	KDM1A 2574/4885RCOR1 2534/4885LDHB 3744/4885
US-10640536-B2	Polymyxins, compositions, methods of making and methods of use	C5, HRH3, SGMS1	KDM1A 2481/4885RCOR1 2521/4885LDHB 3833/4885
US-20170218024-A1	LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF	TLR3, TLR4, TLR5	KDM1A 3849/4885RCOR1 4829/4885LDHB 2174/4885
US-10711040-B2	Low substituted polymyxins and compositions thereof	TLR3, TLR4, TLR5	KDM1A 3849/4885RCOR1 4829/4885LDHB 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.